Olema reports Q2 net loss $20.1M; cash $167.4M; Phase 3 trial on track Q4 2023

Olema Pharmaceuticals, Inc.

2023-Q2 EPS reported -$1.20

Net loss $20.1M for Q2 2023, down from $32.9M in Q2 2022; R&D expenses $18.0M.
Cash, cash equivalents and marketable securities $167.4M as of June 30, 2023, funding operations into Q2 2025.
OPERA-01 pivotal Phase 3 trial of palazestrant (OP-1250) monotherapy to enroll first patient in Q4 2023.
Palazestrant Phase 2 monotherapy data as oral presentation at ESMO Congress October 22, 2023.
Interim Phase 1b/2 combination data with CDK4/6 inhibitors to be presented in Q4 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Olema Pharmaceuticals, Inc. reported financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 8, 2023, Olema Pharmaceuticals, Inc. (the “Company”) reported its financial results for the quarter ended June 30, 2023.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Olema Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-013927

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.